aminopeptidas
n
apn
ec
transmembran
proteas
present
wide
varieti
human
tissu
cell
type
endotheli
epitheli
fibroblast
leukocyt
express
dysregul
inflammatori
diseas
cancer
solid
hematolog
tumor
serv
receptor
coronavirus
natur
synthet
inhibitor
apn
activ
character
inhibitor
reveal
apn
abl
modul
bioactiv
peptid
respons
pain
manag
vasopressin
releas
influenc
immun
function
major
biolog
event
cell
prolifer
secret
invas
angiogenesi
therefor
inhibit
may
lead
develop
anticanc
antiinflammatori
drug
review
provid
updat
biolog
pharmacolog
profil
known
natur
synthet
apn
inhibitor
current
statu
potenti
use
therapeut
agent
discuss
regard
toxic
aminopeptidas
n
ec
apn
metallodepend
integr
membran
proteas
enzym
belong
famili
clan
peptidas
also
call
gluzincin
aminopeptidas
n
consist
amino
acid
short
ntermin
cytoplasm
domain
singl
transmembran
part
larg
cellular
ectodomain
contain
activ
site
enzym
first
isol
pfleider
cellier
pig
kidney
known
sever
differ
name
alanin
aminopeptidas
microsom
aminopeptidas
microsom
leucin
aminopeptidas
aminopeptidas
amino
oligopeptidas
gp
last
year
certain
surfac
molecul
identifi
cluster
differenti
cd
antigen
found
ident
membran
protein
thu
ident
apn
solubl
apn
detect
plasmaserum
urin
mechan
releas
membran
apn
remain
unknown
membranebound
wide
distribut
outsid
hematopoiet
system
epitheli
endotheli
fibroblastcel
type
main
sourc
brush
border
membran
kidney
proxim
tubul
cell
enterocyt
hematopoiet
compart
confin
particular
lineag
predominantli
express
stem
cell
cell
granulocyt
monocyt
lineag
distinct
stage
differenti
therefor
consid
marker
differenti
dysregul
express
membran
andor
solubl
form
observ
mani
diseas
compil
observ
indic
enhanc
apn
level
tumor
cell
melanoma
renal
pancrea
colon
prostat
gastric
thyroid
cancer
tumorinfiltr
cell
renal
lung
cancer
apn
activ
elev
plasma
effus
cancer
patient
apn
activ
neutrophil
patient
affect
rare
adren
gland
tumor
adren
pheochromocytoma
significantli
increas
compar
healthi
control
overexpress
acut
chronic
myeloid
leukemia
anaplast
larg
cell
lymphoma
overexpress
lymphocyt
neutrophil
occur
sever
inflammatori
diseas
chronic
pain
variou
form
joint
effus
rheumatoid
arthriti
multipl
sclerosi
system
sclerosi
system
lupu
erythematosu
polymyositisdermatomyosyti
pulmonari
sarcoidosi
may
therefor
consid
use
clinic
marker
whether
proteas
critic
contribut
patholog
behavior
remain
howev
unknown
review
briefli
summaris
knowledg
structur
mechan
cleavag
integr
current
knowledg
natur
synthet
apn
inhibitor
reader
refer
excel
review
characterist
substrat
specif
variou
aspect
role
review
context
vitro
vivo
use
certain
apn
inhibitor
apn
anchor
plasma
membran
via
uncleav
signal
sequenc
cterminu
type
ii
face
extracellularli
membran
found
dimer
two
non
coval
associ
subunit
rel
molecular
mass
kda
fig
human
gene
clone
subsequ
map
chromosom
possess
two
promot
fig
cdna
sequenc
reveal
presenc
amino
acid
sequenc
hisgluxaaxaahi
zn
bind
motif
found
one
class
metallopeptidas
sitedirect
mutagenesi
indic
extracellular
cystein
molecul
confer
correct
structur
consequ
enzymat
activ
surfac
express
apn
mutat
glutam
acid
aminopeptidas
conserv
region
gamen
motif
lead
inact
enzym
indic
glutam
acid
belong
anion
bind
site
apn
interact
ntermin
aamino
group
substrat
cleav
preferenti
neutral
amino
acid
except
prolin
fig
unsubstitut
nterminu
oligopeptid
biolog
activ
peptid
substrat
cleav
neuropeptid
metand
leuenkephalin
neurokinin
metlysbradykinin
endorphin
spinorphin
vasoact
peptid
kallidin
somatostatin
angiotensin
chemotact
peptid
monocyt
chemotact
nformyl
methionin
leucin
phenylalaninefmlp
apart
hydrolyt
abil
apn
serv
receptor
coronavirus
human
corona
viru
use
apn
enter
alveolar
cell
establish
upper
respiratori
tract
infect
bradykinin
argproproglypheserprophearg
substanc
p
argprolysproglnglnphepheglyleumetnh
natur
peptid
capabl
inhibit
apn
micromolar
concentr
similarli
elev
concentr
leucin
prolin
lalanin
larginin
lglutamin
lmethionin
well
dival
cation
co
zn
mn
ca
ni
inhibit
apn
activ
review
moreov
molecul
broad
spectrum
action
kcn
nan
ammonium
oxal
nethylmaleimid
inhibit
review
apn
activ
also
inhibit
puromycin
lapstatin
nphenylphthalimid
deriv
compound
sever
nphenylhomophthalimid
deriv
like
later
describ
rather
puromycinsensit
aminopeptidas
psa
inhibitor
group
phosphin
dipeptid
analogu
illustr
hphep
ch
tyr
pseudoglutamyl
aminophosphin
peptid
gluc
po
ch
leuala
sever
various
substitut
exemplifi
compound
aaminoboron
deriv
benzyl
deriv
aaminobenzaldehyd
illustr
eclect
set
compound
describ
use
biochem
character
orand
inhibit
proteaseseg
urokinasetyp
plasminogen
activ
dipeptidylpeptidas
iv
differ
aminopeptidas
includ
human
enkephalin
degrad
aminopeptidas
heda
cytosol
leucin
aminopeptidas
lapc
glutamyl
aminopeptidas
apa
arginyl
aminopeptidas
apb
context
also
worth
mention
two
systemat
studi
devot
hydroxyl
natur
occur
flavonoid
baicalein
apigenin
myricetin
relat
compound
asid
activ
neutral
endopeptidas
angiotensinconvert
enzym
exhibit
signific
vitro
inhibitori
effect
toward
apn
formula
ki
ic
inhibit
percentag
enzym
compound
depict
figur
two
recent
public
describ
either
irrevers
inhibit
dpp
enzymat
activ
aqueou
extract
cistu
incanu
l
ace
nep
apn
inhibit
extract
epilobium
angustifolium
deserv
also
quotat
although
borderlin
easi
posit
leav
abovement
studi
deal
nonspecif
compound
target
enzym
incident
reveal
inhibitori
activ
apn
chosen
focu
present
review
data
tightli
dedic
natur
synthet
inhibitor
wide
use
among
natur
occur
inhibitor
microorganismproduc
purifi
microbi
cultur
filtrat
larg
part
gener
bacteria
belong
order
actinomycetal
especi
genera
streptomyc
first
isol
r
green
r
bhagwan
singh
malayan
strain
actynomycet
compound
list
streptomyc
cutter
ncib
year
later
actinonin
also
obtain
anoth
strain
referenc
inhibit
apn
found
competit
substrat
structur
studi
chemic
synthesi
analogu
arous
numer
work
complet
structureact
relationship
investig
deal
anti
bacteri
properti
observ
actinonin
seri
two
close
relat
deriv
ahpavalprohyp
ahpavalpropro
obtain
cultur
broth
streptomyc
neyagawaensi
prepar
sever
novel
synthet
ahpa
deriv
exemplifi
bear
heterocycl
moieti
exhibit
interest
vivo
antitumor
potenc
inhibitori
rate
sarcoma
recent
report
acid
report
slowbind
competit
inhibitor
apn
first
isol
cultur
filtrat
streptomyc
sp
structur
unambigu
determin
sever
enantioselect
synthes
tetrapeptid
report
analogu
also
prepar
context
sar
studi
inhibitor
variou
leucin
arginin
aminopeptidas
effici
inhibitor
lta
hydrolas
howev
spite
mark
toxic
rel
lack
select
toward
exopeptidas
one
use
compound
inhibitori
effect
bestatin
describ
slowbind
competit
inhibitor
apn
schemat
represent
within
activ
site
apn
depict
figur
bestatin
first
isol
cultur
filtrat
streptomyc
olivoreticuli
chemic
structur
subsequ
ascertain
sever
stereoselect
total
synthes
report
prepar
stereoisom
perform
ubenimex
deriv
analogu
parahydroxybestatin
bestatin
thioamid
reduc
bestatin
also
prepar
tripeptid
produc
streptomyc
sp
stereoselect
synthes
recent
report
tetrapeptid
isol
cultur
streptomyc
azureu
structur
unambigu
establish
probestin
describ
competit
inhibitor
apn
also
total
synthes
late
describ
overview
formula
compound
reveal
except
synthet
analogu
prepar
racem
form
possess
absolut
configur
appear
crucial
activ
compar
chiral
framework
also
exist
side
chain
pharmacolog
import
seri
constitut
taxoid
context
worth
point
numer
variou
synthet
approach
build
block
liabl
lead
enantiomer
pure
structur
andor
diastereom
attract
consider
attent
leuhistin
acid
isol
takeuchi
cowork
cultur
broth
bacteria
belong
phylum
firmicut
bacillu
laterosporu
compound
inhibit
apn
competit
manner
substrat
structur
absolut
configur
thereaft
ascertain
group
sever
natur
occur
apn
inhibitor
veget
origin
benzo
c
phenantridin
dioxolo
benzo
chlorid
chelerythrin
close
relat
alkaloid
recent
isol
extract
papaveracea
macleaya
cordata
wild
r
br
compound
show
efficaci
apn
similar
amastatin
bestatin
weaker
inhibitori
effect
dppiv
also
report
e
yellow
natur
phenol
compound
isol
rhizom
asian
perenni
herb
extens
cultiv
tropic
area
belong
zingiberacea
famili
plant
genera
curcuma
exploit
repres
curcuma
longa
l
whose
dri
rhizom
sourc
spice
turmer
wide
employ
food
long
tradit
use
folk
medicin
addit
irrevers
inhibit
potenc
curcumin
consid
oncologist
potenti
cancer
chemoprevent
agent
clinic
trial
context
carri
sever
laboratori
furthermor
curcumin
possess
antiinflammatori
activ
potent
inhibitor
reactiv
oxygengener
enzym
eg
xanthin
dehydrogenaseoxidas
induc
nitric
oxid
synthas
curcumin
hinder
also
initi
carcinogenesi
inhibit
cytochrom
enzym
activ
increas
level
glutathionestransferas
antitumor
effect
promot
progress
stage
attribut
part
arrest
cancer
cell
cycl
phase
induct
apoptosi
also
propos
curcumin
may
suppress
tumor
promot
block
signal
transduct
pathway
target
cell
curcumin
potent
inhibitor
protein
kinas
c
egfreceptor
tyrosin
kinas
ikb
kinas
addit
curcumin
inhibit
activ
nfkb
express
cjun
cfo
cmyc
last
curcumin
propos
proteas
inhibitor
integras
inhibitor
prove
radioprotect
sever
chemic
synthesi
involv
vanillin
report
well
prepar
analogu
design
angiogenesi
inhibitor
abil
inhibit
endotheli
cell
prolifer
acid
pentacycl
compound
wide
present
plant
kingdom
oxid
deriv
betulin
owe
trivial
name
fact
class
lupan
type
triterpen
first
isol
betula
ssp
birch
tree
afterward
betulin
acid
obtain
variou
veget
speci
includ
ancistrocladu
ssp
arbutu
ssp
diospyro
ssp
paeonia
ssp
picramnia
ssp
syzygium
ssp
tetracera
ssp
tryphillum
spp
zizyphu
ssp
one
main
current
sourc
betulin
acid
natur
origin
bark
plane
tree
eg
platanu
acerifolia
employ
patent
procedur
addit
apn
inhibitori
activ
dosedepend
manner
possibl
partial
consequ
inhibitori
potenc
betulin
acid
shown
modul
immun
respons
exhibit
antiinflammatori
properti
block
entri
cell
also
report
select
inhibitor
dna
polymeras
b
induc
apoptosi
tumor
cell
wide
rang
biolog
properti
link
betulin
acid
recent
recapitul
analyz
three
excel
revu
sever
hemisynthesi
start
betulin
via
betulon
acid
variou
natur
occur
betulin
acid
deriv
glycosid
sulfat
dihydroxycinnam
ester
report
knowledg
one
natur
occur
apn
inhibitor
origin
anim
kingdom
symmetr
disulfid
compound
bear
two
hydroxyimino
function
group
bisbromotyrosin
deriv
almost
simultan
first
isol
three
group
unidentifi
marin
spong
probabl
verongida
famili
collect
guam
psammaplysilla
sp
thorectopsamma
xana
structur
unambigu
independ
establish
differ
author
thereaft
psammalin
also
extract
spong
psammaplysilla
purpurea
dysidea
spp
case
author
erron
name
bisprasin
misspel
name
psammalin
dimera
compound
obvious
psammalin
judg
report
formula
aplysinella
rhax
pseudoceratina
purpurea
twospong
associ
poecillastra
wondoensi
jaspi
wondoensi
biosynthet
pathway
propos
format
involv
modifi
cystein
bromotyrosin
knowledg
one
laboratori
prepar
psammalin
carri
start
ltyrosin
n
n
bi
oxim
deriv
also
worth
point
librari
compris
two
hundr
psammalin
type
deriv
recent
prepar
nicola
cowork
use
solut
phase
combinatori
synthesi
aim
evalu
antibacteri
activ
addit
recent
report
abil
inhibit
apn
noncompetit
manner
thu
induc
suppress
vitro
angiogenesi
shown
induc
varieti
biolog
effect
signific
vitro
antibacteri
activ
staphylococcu
aureu
methicillinresist
staphylococcu
aureu
assum
due
abil
inhibit
dna
gyras
ii
cytotox
variou
human
tumor
cell
line
iii
increas
ca
releas
heavi
fraction
skelet
muscl
sarcoplasm
reticulum
iv
inhibit
topoisomeras
ii
leucin
aminopeptidas
farnesyl
protein
transferas
mycothiolsconjug
amidas
chitinas
histon
deacetylas
dna
methyltransferas
dna
replic
target
polymeras
aprimas
antifung
insecticid
activ
report
chemic
structur
apn
inhibitor
enzym
inhibit
valu
depict
figur
sever
synthet
small
molecul
belong
variou
chemic
famili
report
inhibit
apn
activ
aaminomethylketon
hydrochlorid
valin
methyl
keton
hydrochlorid
alkyl
dcystein
display
also
effici
competit
apn
inhibit
among
five
ester
test
optim
inhibitori
activ
observ
nbutyl
deriv
deriv
hydrochlorid
report
effici
select
competit
inhibitor
apn
compound
affect
apa
apb
poorli
inhibit
lapc
deriv
respect
competit
inhibitor
apn
moder
activ
lapc
apb
acid
deriv
constitut
class
product
whose
parent
compound
show
antiangiogen
properti
seri
product
bear
nitro
group
acet
acid
prove
potent
apn
inhibitor
act
revers
bind
catalyt
site
enzym
compound
present
advantag
exhibit
toxic
toward
cultur
human
cell
induc
apoptosi
inact
proteas
ace
nep
gglutamyl
transpeptidas
cathepsin
g
dppiv
acetamid
acetamid
recent
identifi
potent
apn
inhibitor
act
dosedepend
manner
inact
metalloenzym
alap
design
synthet
apn
inhibitor
often
reli
structureact
studi
base
activ
site
model
deriv
structur
data
obtain
zincdepend
proteas
thermolysin
crystal
varieti
inhibitor
molecul
capabl
interact
least
subsit
apn
strong
zincchel
group
design
accord
criteria
aaminophosphin
acid
deriv
prepar
prove
potent
apn
inhibitor
accord
pattern
model
synthesi
analog
iodo
deriv
rb
next
perform
give
rise
radiolabel
rb
repres
use
probe
investig
physiolog
role
apn
context
sever
baminothiol
exemplifi
conceiv
synthes
research
field
extend
elabor
seri
roqu
cowork
novel
sulfurcontain
molecul
capabl
inhibit
apn
prepar
work
baminothiol
two
product
emerg
pc
similar
activ
site
apn
membranebound
proteas
neutral
endopeptidas
nep
led
idea
mix
inhibitor
could
develop
select
framework
bear
strong
zincchel
group
residu
abl
interact
least
one
subsit
peptidas
first
dual
inhibitor
develop
hydroxamatecontain
molecul
kelatorphan
rb
whose
sever
analog
synthes
found
also
potent
inhibitor
leukotrien
hydrolas
howev
import
water
solubl
compound
impedi
cross
bloodbrain
barrier
consequ
obtain
good
bioavail
anoth
strategi
involv
lipophil
deriv
led
synthesi
rb
n
r
butyldithio
lphenylalanin
benzyl
ester
rb
n
butyldithio
lalanin
benzyl
ester
two
dual
inhibitor
disulfid
bridg
link
apn
inhibitor
pc
analog
phenylalanin
analog
st
case
alanin
analogu
case
benzyl
ester
thiorphan
specif
nep
inhibitor
fig
mix
inhibitor
present
advantag
possess
abovement
disulfid
bond
rel
stabl
plasma
contrast
rapid
cleavag
brain
thu
allow
deliveri
nep
apn
inhibitor
activ
form
toward
respect
target
develop
mix
inhibitor
constitut
import
advanc
research
new
antihypertens
novel
antinocicept
drug
devoid
opioid
side
effect
review
recent
new
gener
phosphin
acid
deriv
prepar
nepapn
dual
inhibitor
compound
success
test
context
chemic
structur
apn
inhibitor
enzym
inhibit
valu
outlin
figur
effect
describ
inhibitor
cell
behavior
assay
vitro
approach
tabl
provid
summari
relev
studi
human
system
actinonin
bestatin
probestin
psammaplin
mm
concentr
shown
reduc
growth
human
tb
lymphocyt
dendrit
cord
blood
cell
human
myeloid
lymphoid
cell
line
well
prolifer
variou
tumor
endotheli
cell
line
question
central
apn
inhibit
studi
cell
growth
turn
apn
inhibitor
apn
inhibitor
may
alter
process
unknown
growth
factor
directli
involv
regul
growth
addit
sever
studi
indic
inhibitor
like
actinonin
probestin
may
transmit
intracellulartransduct
signal
interf
map
kinas
signal
pathway
second
cell
signal
pathway
involv
protooncogen
appear
also
affect
inhibit
apn
actinonin
point
actinonin
mm
concentr
inhibit
growth
myeloid
lymphoma
cell
line
suggest
effect
induc
actinonin
like
mediat
moreov
amastatin
concentr
inhibit
apn
activ
found
without
effect
growth
human
myeloid
cell
line
bestatinmedi
cell
growth
arrest
associ
induct
cell
matur
clonogen
gmcfu
granulocytemacrophag
coloni
form
unit
cell
human
immatur
derivedbon
marrow
cell
similarli
treatment
human
myeloid
cell
line
bestatin
induc
phenotyp
chang
characterist
macrophag
neutrophil
matur
cell
growth
arrest
induc
apn
inhibitor
correl
altern
secret
proinflammatori
immunosuppress
cytokin
involv
pathophysiolog
process
bestatin
mm
increas
level
secret
endotheli
cell
releas
mous
periton
macrophag
releas
concanavalinstimul
cell
probestin
induc
synthesi
releas
recent
observ
point
involv
apn
process
apoptosi
program
cell
death
bestatin
actinonin
start
mm
induc
apoptosi
larg
varieti
cell
line
ie
myeloid
lymphoid
jurkat
bjab
boe
cell
carcinoma
fibrosarcoma
cervic
lung
carcinoma
betulin
acid
induc
apoptosi
colon
cancer
cell
line
mm
acut
leukemia
cell
mm
gener
way
cell
motil
migrat
invas
may
influenc
process
chemokin
andor
degrad
extracellular
matrix
ecm
two
small
protein
chemotact
activ
fmlp
vitro
hydrolyz
regard
current
data
report
potenti
action
apn
inhibitor
migrat
actinonin
amastatin
abl
enhanc
chemotact
respons
human
neutrophil
toward
fmlp
one
explan
effect
actinonin
amastatin
would
inhibitor
prevent
inactiv
fmlp
apn
enhanc
fmlpmediat
chemotact
respons
howev
underlin
inhibitor
weakli
inhibit
apn
enzymat
activ
rang
concentr
effect
neutrophil
migrat
apn
inhibit
actinonin
bestatin
significantli
enhanc
vitro
migrat
eosinophil
across
huvec
monolay
moreov
actinonin
bestatin
well
leuhistin
mm
significantli
block
invas
variou
human
metastat
tumor
cell
reconstitut
basement
membran
matrigel
latter
data
suggest
apn
could
indirectli
involv
type
iv
collagen
degrad
activ
type
iv
recent
studi
demonstr
solubl
induc
vitro
chemotact
migrat
lymphocyt
bestatin
high
concentr
mm
abolish
process
suggest
enzymat
activ
apn
respons
chemotact
activ
demonstr
particip
apn
angiogenesi
come
recent
studi
block
apn
activ
apn
inhibitor
result
perturb
angiogen
assay
tabl
express
human
umbil
vein
endotheli
cell
huvec
angiogen
normal
vasculatur
bestatin
betulin
acid
amastatin
curcumin
psammaplin
mm
abrog
abil
huvec
cultur
matrigel
organ
capillari
network
without
alter
prolifer
rate
contrast
one
studi
underlin
proangiogen
effect
bestatin
mm
instead
caus
matrix
degrad
stimul
invas
microvascular
endotheli
cell
fibrin
matrix
chorioallanto
membran
cam
assay
angiogen
respons
determin
measur
number
avian
extraembryon
capillari
vessel
grow
within
matrix
polym
contain
angiogen
molecul
fibroblast
growth
place
yolk
sac
membran
day
embryo
cultur
chick
vasculatur
express
phenotyp
subsequ
treatment
bestatin
actinonin
mg
inhibit
angiogenesi
mous
retin
neovascular
model
bestatin
mgmous
lead
blockad
hypoxiainduc
retin
neovascular
mice
intraperiton
administr
bestatin
mgkgday
orthotop
implant
melanoma
cell
mice
reduc
number
vessel
orient
toward
establish
primari
tumor
mass
dorsal
side
mice
compil
data
document
involv
pathophysiolog
event
cancer
inflamm
infect
pain
suppress
come
studi
block
apn
activ
rodent
model
tabl
studi
rat
indic
administr
bestatin
lead
inhibit
fetal
growth
induct
placent
apoptosi
vivo
anticanc
activ
bestatin
betulin
acid
report
capac
inhibit
growth
syngen
tumor
leukemia
melanomaovarianhepatomagastr
carcinoma
cell
implant
mice
rat
dose
low
mgkg
bestatin
mgkg
betulin
acid
use
studi
moreov
high
dose
mgkg
lead
cytotox
effect
mice
bestatin
leuhistin
betulin
acid
investig
antiinflammatori
properti
betulin
acid
possess
moder
antinflammatori
abil
rel
high
concentr
mgkgmous
iv
contrast
bestatin
leuhistin
inhibit
acut
inflamm
associ
accumul
polymorphonuclear
neutrophil
mous
model
mgkg
iv
moreov
oral
administr
bestatin
mgkg
carcinomabear
mice
induc
gener
cytotox
cell
nk
natur
killer
cell
angiotensin
ii
iii
two
peptid
effector
brain
renninangiotensin
system
particip
control
blood
pressur
increas
water
consumpt
vasopressin
releas
hypertens
rat
infus
amastatin
nmolmin
iv
prevent
degrad
angiotensin
associ
blood
pressur
decreas
mous
brain
apn
inhibit
mg
inject
intracerebroventricularli
increas
half
life
angiotensin
iii
result
enhanc
vasopressin
releas
sever
studi
report
bestatin
exert
antiinfecti
properti
augment
host
resist
bacteri
viral
fungal
experiment
infect
mice
induc
neutrophil
macrophag
activ
enhanc
antibodi
product
final
central
nervou
system
enkephalin
modul
respons
pain
stimuli
inactiv
apn
membranebound
proteas
neutral
endopeptidas
led
idea
inhibit
enzym
alon
combin
could
achiev
clinic
effici
analgesia
actinonin
well
dual
inhibitor
mgkg
iv
mgkg
ip
exhibit
analges
properti
chronic
pain
rat
mice
first
clinic
trial
bestatin
mgdaili
use
treat
patient
acut
chronic
myeloid
leukemia
aml
cml
lymphoma
therapeut
efficaci
demonstr
prolong
surviv
patient
aml
lymphoma
promot
graft
versu
leukemia
effect
patient
follow
allogen
bone
marrow
transplant
phase
ib
trial
activ
blood
monocyt
increas
lymphocyt
ratio
observ
hodgkin
nonhodgkin
lymphoma
patient
treat
oral
high
dose
bestatin
day
follow
autolog
bone
marrow
transplant
phase
iii
trial
resect
stage
squamou
cell
lung
carcinoma
surviv
statist
better
patient
treat
bestatin
year
postop
adjuv
therapi
receiv
placebo
use
defin
clinic
subgroup
patient
variou
malign
inflammatori
diseas
use
natur
synthet
apn
inhibitor
reveal
particip
control
major
biolog
process
prolifer
secret
apoptosi
dysregul
tumor
often
link
tumor
invas
angiogenesi
studi
nonhematopoiet
cell
suggest
may
influenc
cell
migrat
invas
apn
inhibitor
shown
alter
angiogenesi
vitro
vivo
assay
document
evid
underlin
antiangiogen
proangiogen
effect
bestatin
figur
summar
current
understand
involv
apn
inhibitor
modul
event
detail
molecular
mechan
underli
effect
howev
yet
unclear
importantli
requir
apn
process
mostli
confirm
studi
express
block
neutral
antibodi
antisens
oligonucleotid
enhanc
use
transfect
howev
point
apn
inhibitor
lack
tight
specif
inhibit
membranebound
metalloproteas
secret
matrix
metalloproteinas
mmp
tabl
exampl
bestatin
interact
leucylaminopeptidas
oxytocinas
leuap
aminopeptidas
b
ec
apb
aminopeptidas
w
ec
apw
thu
suggest
observ
chemotherapeut
action
bestatin
may
due
inhibit
cell
surfac
peptidas
actinonin
recent
shown
interact
human
peptid
deformylas
meprin
ec
endopeptidas
amastatin
probestin
low
micromolar
rang
mm
inhibit
aminopeptidas
ec
apa
apw
leuhistin
inhibit
apa
apb
degre
apn
curcumin
betulin
acid
block
express
collagenas
activ
inhibit
nfkb
activ
addit
use
avail
apn
inhibitor
experiment
situat
reveal
complex
effect
cell
behavior
mention
paragraph
cell
line
equal
sensit
growthinhibitori
effect
actinonin
mm
thu
emphas
actinonin
may
induc
unspecif
cytotox
sideeffect
moreov
betulin
acid
inhibit
tube
format
bovin
aortic
endotheli
cell
concentr
effect
cell
viabil
vivo
apn
activ
endotheli
cell
thu
indic
apnindepend
mode
action
betulin
acid
togeth
observ
emphas
need
specif
target
apn
inhibitor
evalu
action
pathophysiolog
process
futur
consider
given
obtent
threedimension
structur
apn
determin
nmr
spectroscopi
help
apn
inhibitor
design
strategi
vitro
vivo
studi
promis
non
cytototox
apn
inhibitor
psammaplin
phosphon
deriv
acid
deriv
also
requir
clinic
prescrib
apn
inhibitor
anticanc
antiinflammatori
agent
